John Ratliff - Laboratory Chief Executive Officer - Covance Drug Development

LH Stock  USD 216.57  3.05  1.43%   

CEO

Mr. John D. Ratliff is Chief Executive Officer Covance Drug Development of the Company. Mr. Ratliff is a highly respected biopharmaceutical leader, with extensive experience in increasingly important roles in the industry. Most recently, he served as president and CEO of HUYA Bioscience International, a leader in globalizing biopharma innovation. Mr. Ratliffs experience in biopharma also includes nearly ten years at Quintiles, joining as Chief Financial Officer in 2004, becoming Chief Operating Officer in 2006, and President and COO in 2010. He led Quintiles global services organization, with its clinical research, commercial, consulting, and lab operations, and was a member of the companys Board of Directors. Mr. Ratliff is chairman of the board of the Association of Clinical Research Organizations. Previous roles throughout his career also include serving as Chief Financial Officer at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and in positions of increasing responsibility during his 19year tenure at IBM. since 2019.
Age 58
Tenure 5 years
Address 358 South Main Street, Burlington, NC, United States, 27215
Phone336 229 1127
Webhttps://www.labcorp.com
Ratliff holds a Bachelor’s degree in Industrial and Systems Engineering, summa cum laude, from the Georgia Institute of Technology and a Master’s degree in Business Administration from Duke University.

Laboratory Management Efficiency

The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to 0.08. The current Return On Assets is estimated to decrease to 0.02. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.
The company reports 5.95 B of total liabilities with total debt to equity ratio (D/E) of 0.63, which is normal for its line of buisiness. Laboratory has a current ratio of 1.7, which is generally considered normal. Debt can assist Laboratory until it has trouble settling it off, either with new capital or with free cash flow. So, Laboratory's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Laboratory sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Laboratory to invest in growth at high rates of return. When we think about Laboratory's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

CEO Age

Christopher RowlandMedigus Ltd ADR
56
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina. Laboratory Corp operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 75000 people. Laboratory (LH) is traded on New York Stock Exchange in USA. It is located in 358 South Main Street, Burlington, NC, United States, 27215 and employs 56,950 people. Laboratory is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Laboratory Leadership Team

Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Klitgaard, President- Enlighten Health
Paul Surdez, IR Contact Officer
Glenn Eisenberg, Chief Financial Officer, Executive Vice President
Deborah Tanner, CEO - Covance Drug Development (Covance)
Stephen Anderson, Vice President Investor Relations
Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer
Judith Seltz, Chief Human Resource Officer, Executive Vice President
Michelle Abelson, Laboratory Operations
Sanders Williams, Independent Director
John Ratliff, Chief Executive Officer - Covance Drug Development
Kerrii Anderson, Independent Director
JD MD, President EVP
Amy Summy, Executive Vice President Chief Marketing Officer
Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain
Peter Wilkinson, Senior Vice President, Chief Accounting Officer
Paul MD, Ex Devel
Marcia Eisenberg, Chief VP
Lisa Uthgenannt, Chief Human Resource Officer, Senior Vice President
Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer
D Gilliland, Independent Director
Gary Huff, CEO, LabCorp Diagnostics
JeanLuc Belingard, Independent Director
Clarissa Willett, IR Contact Officer
Kathryn Wengel, Independent Director
Peter Neupert, Lead Independent Director
Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development
James Boyle, Executive VP and CEO of Labcorp Diagnostics
Richelle Parham, Independent Director
Robert Williams, Independent Director
Jeffrey Davis, Independent Director
Christin ODonnell, Vice Relations
Chas Cook, VP Relations
Garheng Kong, Independent Director
Gary Gilliland, Independent Director
David King, Chairman of the Board, President, Chief Executive Officer
Adam Schechter, Chairman of the Board, President, Chief Executive Officer
Mark Brecher, Senior Vice President Chief Medical Officer
Samuel Eberts, Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer
Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
Edward Dodson, Chief Accounting Officer and Sr. VP
Scott Frommer, Vice President - Investor Relations
Robert Mittelstaedt, Lead Independent Director
MPH MD, Pres VP

Laboratory Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Laboratory offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Laboratory's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Laboratory Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Laboratory Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more detail on how to invest in Laboratory Stock please use our How to Invest in Laboratory guide.
Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Laboratory Stock analysis

When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Managers
Screen money managers from public funds and ETFs managed around the world
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.46)
Dividend Share
2.88
Earnings Share
4.33
Revenue Per Share
139.628
Quarterly Revenue Growth
0.035
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.